Why this CAR T advance matters: Complete remissions without chemotherapy at doses as low as 250,000 cells/kg

Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and mount potent anti-tumor responses. These properties make them an attractive candidate for next-generation CAR T-cell therapies. However, their clinical potential has not previousl